Robin H Lachmann

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi request reprint alpha-glucosidase (CHO) (Genzyme)
    Robin H Lachmann
    University of Cambridge, Department of Medicine, Box 157, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
    Curr Opin Investig Drugs 5:1101-10. 2004
  2. ncbi request reprint Substrate reduction therapy for glycosphingolipid storage disorders
    R H Lachmann
    Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge, UK
    Expert Opin Investig Drugs 10:455-66. 2001
  3. pmc Herpes simplex virus-based vectors
    Robin Lachmann
    Department of Medicine, University of Cambridge, Cambridge, UK
    Int J Exp Pathol 85:177-90. 2004
  4. ncbi request reprint Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C
    Robin H Lachmann
    Department of Medicine, University of Cambridge, Cambridge CB2 2QQ, UK
    Neurobiol Dis 16:654-8. 2004
  5. ncbi request reprint Herpes simplex virus latency
    Robin Lachmann
    Department of Medicine, Box 157, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Expert Rev Mol Med 5:1-14. 2003
  6. ncbi request reprint Miglustat. Oxford GlycoSciences/Actelion
    Robin H Lachmann
    University of Cambridge, Department of Medicine, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Curr Opin Investig Drugs 4:472-9. 2003
  7. ncbi request reprint Latency associated promoter transgene expression in the central nervous system after stereotaxic delivery of replication-defective HSV-1-based vectors
    C G Scarpini
    Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK
    Gene Ther 8:1057-71. 2001
  8. pmc Herpes simplex virus type 1 promoter activity during latency establishment, maintenance, and reactivation in primary dorsal root neurons in vitro
    J L Arthur
    Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    J Virol 75:3885-95. 2001
  9. ncbi request reprint Gene transfer with herpes simplex vectors
    R H Lachmann
    Department of Medicine, Box 157, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Curr Opin Mol Ther 1:622-32. 1999
  10. ncbi request reprint Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders
    Robin H Lachmann
    Charles Dent Metabolic Unit, The National Hospital for Neurology and Neurosurgery, London, UK
    Drugs Today (Barc) 42:29-38. 2006

Detail Information

Publications11

  1. ncbi request reprint alpha-glucosidase (CHO) (Genzyme)
    Robin H Lachmann
    University of Cambridge, Department of Medicine, Box 157, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
    Curr Opin Investig Drugs 5:1101-10. 2004
    ..By July 2004, enrollment was completed in two clinical trials and an observational study in adults. Genzyme was planning to file for regulatory approval in Europe during 2004, followed by filings in the US and Japan in mid-2005...
  2. ncbi request reprint Substrate reduction therapy for glycosphingolipid storage disorders
    R H Lachmann
    Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge, UK
    Expert Opin Investig Drugs 10:455-66. 2001
    ..This trial provides a proof-of-principle for the use of this approach in a wide range of GSL lysosomal storage diseases...
  3. pmc Herpes simplex virus-based vectors
    Robin Lachmann
    Department of Medicine, University of Cambridge, Cambridge, UK
    Int J Exp Pathol 85:177-90. 2004
    ....
  4. ncbi request reprint Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C
    Robin H Lachmann
    Department of Medicine, University of Cambridge, Cambridge CB2 2QQ, UK
    Neurobiol Dis 16:654-8. 2004
    ..These observations support the use of SRT in patients with this devastating neurodegenerative disease...
  5. ncbi request reprint Herpes simplex virus latency
    Robin Lachmann
    Department of Medicine, Box 157, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Expert Rev Mol Med 5:1-14. 2003
    ..This review focuses on what we have learned from molecular studies in model systems of HSV latency, and the implications these findings have for treating recurrent HSV disease...
  6. ncbi request reprint Miglustat. Oxford GlycoSciences/Actelion
    Robin H Lachmann
    University of Cambridge, Department of Medicine, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Curr Opin Investig Drugs 4:472-9. 2003
    ..In November 2002, miglustat received EU approval for the treatment of Gaucher disease and was launched in the UK in March 2003 by Actelion. At this time, additional EU launches were expected over the next few months...
  7. ncbi request reprint Latency associated promoter transgene expression in the central nervous system after stereotaxic delivery of replication-defective HSV-1-based vectors
    C G Scarpini
    Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK
    Gene Ther 8:1057-71. 2001
    ....
  8. pmc Herpes simplex virus type 1 promoter activity during latency establishment, maintenance, and reactivation in primary dorsal root neurons in vitro
    J L Arthur
    Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    J Virol 75:3885-95. 2001
    ....
  9. ncbi request reprint Gene transfer with herpes simplex vectors
    R H Lachmann
    Department of Medicine, Box 157, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Curr Opin Mol Ther 1:622-32. 1999
    ....
  10. ncbi request reprint Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders
    Robin H Lachmann
    Charles Dent Metabolic Unit, The National Hospital for Neurology and Neurosurgery, London, UK
    Drugs Today (Barc) 42:29-38. 2006
    ..This article addresses both the preclinical and clinical development of miglustat for treatment of type 1 Gaucher's disease, as well as related neuronopathic glycosphingolipidoses...
  11. ncbi request reprint Glucosylated free oligosaccharides are biomarkers of endoplasmic- reticulum alpha-glucosidase inhibition
    Dominic S Alonzi
    Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK
    Biochem J 409:571-80. 2008
    ..In mouse and human urine, glucosylated FOS were detected as a result of transrenal excretion and provide unique and quantifiable biomarkers of ER-glucosidase inhibition...